Boehringer Ingelheim, Cognizant and Veeva connect using 'technology ecosystem'

By Liza Laws

- Last updated on GMT

 © Getty Images
© Getty Images

Related tags Technology Data management Artificial intelligence Clinical data Research

Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.

IT and consultant company Cognizant and research-driven biopharma company, Boehringer Ingelheim will be working together to ‘advance the speed and quality of medicinal therapy development’ they say. They will use the Veeva Development Cloud - an operating system for product development that brings together applications for clinical, quality, regulatory, and safety to help organizations drive end-to-end business processes.

While an ecosystem is usually considered to include living organisms, it is a phrase that has been coined by Harvard business strategist, James Moore, who implies that businesses don’t function as single entities but as ‘part of an ecosystem supporting each other directly or indirectly.’

Uli Brodl, senior vice president, global clinical development at Boehringer Ingelheim, said: “Achieving an end-to-end platform to help speed the development of life-changing therapies has been an elusive goal for many organizations, and we're making that vision a reality.

“Our collaborations with Cognizant and Veeva are empowering us to advance this important program that will positively impact patient lives.”

The ecosystem known as One Medicine Platform, Cognizant and Boehringer say, is expected to be one of the biggest of its kind by Veeva technology.

Cognizant initiated the Boehringer Ingelheim engagement with an analysis of the biopharmaceutical manufacturer's business and technology, followed by development of the program roadmap and agile methodology for system integration.

Collaborating with Veeva, Cognizant is now providing services including program management, system architecture and design, training, data migration, integration, testing and validation services. 

“Utilizing advanced technologies to improve the quality and delivery of novel medicines is a must for innovative pharmaceutical companies, and Boehringer Ingelheim stands out for their forward thinking in pursuing development of the One Medicine Platform," said Srini Shankar, global head of Cognizant Life Sciences.

"Veeva has been recognized as one of the fastest growing life sciences technology companies, and Cognizant is a skilled system integrator with the expertise necessary to simultaneously implement multiple Veeva platforms. We are proud to be working together to set new precedents in the way clinical, regulatory, and quality functions come together to help accelerate the delivery of new life-saving therapies." 

Related news

Show more

Related products

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Related suppliers

Follow us


View more